Viewing StudyNCT02511184



Ignite Creation Date: 2024-05-06 @ 7:19 AM
Last Modification Date: 2024-10-26 @ 11:47 AM
Study NCT ID: NCT02511184
Status: TERMINATED
Last Update Posted: 2019-07-01
First Post: 2015-07-22

Brief Title: Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
Sponsor:
Organization: Pfizer

Study Design

Study Type: INTERVENTIONAL
Expanded Access Type Individual: None
Expanded Access Type Intermediate: None
Expanded Access Type Treatment: None
Patient Registry: None
Target Duration: None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention: None
Bio Spec Description: None
Enrollment Count: 9
Enrollment Type: ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
Name
PHASE1
Observational Models:
Time Perspective List:
Who Masked List: